Chris Starr, Ph.D.
Dr. Starr has extensive experience in developing and commercializing biologic and small molecule therapeutics in the orphan genetic disease space through six drug approvals and multiple commercial launches. Dr. Starr co-founded was co-founder and Chief Executive Officer of Raptor Pharmaceuticals since its inception in 2006 until 2015. As Chief Executive Officer, Dr. Starr built Raptor from a startup to a 130 person NASDAQ-listed company with one approved product and two Phase 2 programs. Raptor was acquired by Horizon Pharma in 2016 for $800 mil. Prior to starting Raptor, Dr. Starr co-founded BioMarin Pharmaceuticals Inc. in 1997 where he last served as Senior Vice President and Chief Scientific Officer until 2006 responsible for managing a Scientific Operations team of 181 research, process development, manufacturing and quality personnel through the successful development of commercial manufacturing processes for its enzyme replacement products, and supervised the cGMP design, construction and licensing of BioMarin’s proprietary biological manufacturing facility. Dr. Starr was recipient of a National Research Council Associate Award while a post-doc at the National Institutes of Health in Bethesda, MD. Dr. Starr earned a B.S. from Syracuse University and a Ph.D. in Biochemistry and Molecular Biology from the State University of New York Health Science Center.
Gregory Enns, M.D.
Dr. Enns is a Professor of Pediatrics and Director of the Biochemical Genetics Program at Stanford University. After receiving his medical degree from the University of Glasgow, he trained in Pediatrics at Children's Hospital Los Angeles, and in Clinical Genetics and Clinical Biochemical Genetics at the University of California, San Francisco.
He has extensive experience in the diagnosis and management of inborn errors of metabolism, including congenital disorders of glycosylation, mitochondrial disorders, and lysosomal storage disorders. Dr. Enns also performs translational research focusing on the development of a sensitive panel of redox biomarkers to study disorders of energy metabolism, and participates in clinical trials aimed at developing novel treatments for inborn errors of metabolism.
Matt Wilsey is a Silicon Valley entrepreneur, angel investor, and advisor. In addition to consumer products and services, Matt invests in and advocates in biomedical research, drug development, and genetic sequencing technologies. Before moving to the investment side, he spent many years as a front-line operator. Most recently, Matt was Co-Founder and Chief Revenue Officer of Card Spring, a payment infrastructure company that was acquired by Twitter. Previously, Matt ran West coast sales and business development for Howcast.com. Before Howcast, Matt worked for Kohlberg Kravis Roberts (KKR) on the Capital Markets team. Prior to that, Matt spent five years as a Co-Founder and Vice President of Business Development at Zazzle.com.
He started his career serving in various roles at the White House and the Department of Defense. Matt became a rare disease advocate after his daughter Grace was born with Ngly1 deficiency. The Grace Wilsey Foundation has founded 20 research teams accounting for over 50 scientists in 3 countries with the sole purpose of curing the disease. Matt holds a B.A. from Stanford University and a M.B.A. from Stanford’s Graduate School of Business.